Innovita is at the forefront of Medical Innovation with a significant breakthrough in cancer treatment protocols.
Our latest advancement involves the enhancement of Dendritic Cell Vaccine (DCV) production from a single blood draw.
Our specialists have determined that the optimal treatment involves four doses of Dendritic Cell Vaccines (DCV), each containing approximately 5 million cells, administered over seven weeks. This regimen has been optimized to elicit the best patient response, with successful treatments potentially providing immune responses for up to two years.
Recent technological improvements in our labs now enable us to harvest and prime additional Dendritic Cell Vaccines (DCV) from the same initial blood sample. We can then store these for up to 3 years. This storage process is analogous to fertility preservation techniques and allows for the future administration of "booster" treatments, enhancing the immune response against cancer as needed.
Patients may receive these additional treatments at intervals of three, twelve, or eighteen months or more, as recommended by our specialists during follow-up consultations. The actual number of additional vaccines created depends on the quality of the blood sample and the efficiency of our laboratory processes.
To facilitate the production of these extra vaccines, we coordinate with our laboratory to continue the processing of cells post the initial vaccine production. Whilst we cannot guarantee additional vaccine production due to varying blood qualities, our expertise gives us confidence in our ability to generate these supplementary doses.
Additional vaccines are offered at a significantly reduced cost compared to the initial treatment. If we cannot produce the additional vaccines, we will issue a full refund for the unproduced doses, despite incurring laboratory expenses.
Innovita remains committed to pioneering cancer treatment and care. Our collaborative efforts with patients and continuous innovation in laboratory practices aim to provide renewed hope and enhanced quality of life.
Additional dendritic cell vaccines from the original blood draw.
Additional dendritic cell production intended for future use from either the original autologous or allogeneic (direct relative) blood draw.
Background: The optimum protocol, according to the research and experience of our specialist, for dendritic cell vaccines is 4 applications of nominally 5 million cells each vaccine applied over a 7-week period.
The response rate from the patient is optimised at this protocol and when a good response is achieved the effect of the DCV treatment, we believe, can last for up to a couple of years.
Recent advances in technology and laboratory ability at our facility can allow us, at Innovita, to potentially harvest and prime additional dendritic cell vaccines from the same original blood draw and store these for future use (much like fertility treatments).
These extra dendritic cell vaccines require more lab time, more labour and attention and more peptides and natural agents to mature and prime but are less expensive than the first DCV’s as the process is already underway.
The ability to do this is very dependent on the blood quality and is not guaranteed.
After the initial DCV treatments (4 per the protocol), the patient may have more treatments at 3 months, 12 months, or 18 months (timing to be agreed with our specialists during follow ups) after this and it can act as a “booster” for a renewed response against the cancer if required in the future.
This very much depends on the blood quality and the laboratory processes. It may be an additional 2, 3 or 4 or even more. An additional 2 is expected to be sufficient as a booster but we would try to produce an additional 4 as a second round if possible. The production and storage (at -150 to -195c) is done at the laboratory and the additional cells/treatments are available on call.
We need to advise the laboratory before the initial production begins so that they continue the process and try to produce additional treatments for storage. There are no guarantees that the laboratory will be able to produce additional vaccines but we are confident subject to reasonable blood/cell quality that we have the ability to do so.
Cost: The patient will be quoted an additional cost per vaccine (2,3, 4 or more) which will be substantially less expensive than the original production.
Refund: If the additional vaccines cannot be produced then a full refund of this option will promptly be credited to the patient for the vaccines that were not produced even though we will have incurred additional lab costs.
Cookie | Duration | Description |
---|---|---|
CookieLawInfoConsent | 1 year | Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie. |
cookielawinfo-checkbox-advertisement | session | Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category . |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.